ID

17654

Descripción

Sponsor: OSI Pharmaceuticals Information provided by (Responsible Party): Astellas Pharma Inc (OSI Pharmaceuticals) A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent Tarceva® (erlotinib) following complete tumor resection with or without adjuvant chemotherapy in patients with stage IB-IIIA non-small cell lung carcinoma who have EGFR-positive tumors. See https://clinicaltrials.gov/ct2/show/NCT00373425 Part of study: Open-label Tarceva Consent and Eligibility

Link

https://clinicaltrials.gov/ct2/show/NCT00373425

Palabras clave

Versiones (2)
  1. 2/8/16 2/8/16 -
  2. 27/9/16 27/9/16 -
Subido en

27 de septiembre de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Open-label Tarceva, Tarceva in NSCLC patients who have EGFR-positive tumors DRKS00001485 NCT00373425

Inglés

Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 formularios  
Open Label Tarceva Consent
Descripción

Open Label Tarceva Consent

Date addendum to main study consent was signed:
Descripción

Consent date

Tipo de datos

date

Alias
UMLS CUI [1]
C2985782
Open-label Tarceva: please check one
Descripción

Open-label Tarceva

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C1709323
UMLS CUI [1,2]
C1135136
Open-label Tarceva Eligibility
Descripción

Open-label Tarceva Eligibility

Open-label Tarceva Eligibility: Not Applicable
Descripción

Open-label Tarceva Eligibility

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1516637
Did the patient meet all of the eligibility criteria to receive open-label Tarceva?
Descripción

Eligibility Criteria: OSI-774-302 Protocol Version 2, 21 November 2007, Appendix 12.9

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1302261
If No, which of the 4 criteria was/were not met? Criteria 1 met?
Descripción

Eligibility Criteria

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1516637
If No, which of the 4 criteria was/were not met? Criteria 2 met?
Descripción

Eligibility Criteria

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1516637
If No, which of the 4 criteria was/were not met? Criteria 3 met?
Descripción

Eligibility Criteria

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1516637
If No, which of the 4 criteria was/were not met? Criteria 4 met?
Descripción

Eligibility Criteria

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1516637
lf any eligibility criteria were not met, was an exemption granted by OSI?
Descripción

Exemption

Tipo de datos

integer

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348482
Investigator Signature
Descripción

Investigator Signature

Investigator's Signature:
Descripción

I have reviewed all data for this patient's eligibility and confirm that consent has been obtained in accordance with the GCP Directive (2005/28/EC) or EU Directive (2001/20/EC) and other applicable GCP requirements.

Tipo de datos

text

Alias
UMLS CUI [1]
C2346576
Date
Descripción

Investigator Signature Date

Tipo de datos

date

Alias
UMLS CUI [1,1]
C2346576
UMLS CUI [1,2]
C0011008
Volver a la parte superior de la página

Similar models

Open-label Tarceva Consent and Eligibility, Tarceva in NSCLC patients who have EGFR-positive tumors NCT00373425

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
Open Label Tarceva Consent
Consent date
Item
Date addendum to main study consent was signed:
date
C2985782 (UMLS CUI [1])
Item
Open-label Tarceva: please check one
integer
C1709323 (UMLS CUI [1,1])
C1135136 (UMLS CUI [1,2])
Open-label Tarceva
Code List
Open-label Tarceva: please check one
CL Item
Patient to receive open-label Tarceva for up to two years and will be followed for all On-treatment, Post-treatment and Long-term Follow-up Assessments according to the protocol. (Complete Open-label Baseline Assessments.) (1)
CL Item
Patient not to receive open-label Tarceva but will remain in the study and continue to be followed for all Post-treatment and Long-term Follow-up Assessments. (Complete Post-treatment Assessments and Long-term Follow-up Assessments.) (2)
Item Group
Open-label Tarceva Eligibility
Open-label Tarceva Eligibility
Item
Open-label Tarceva Eligibility: Not Applicable
boolean
C1516637 (UMLS CUI [1])
Eligibility
Item
Did the patient meet all of the eligibility criteria to receive open-label Tarceva?
boolean
C1302261 (UMLS CUI [1])
Eligibility Criteria
Item
If No, which of the 4 criteria was/were not met? Criteria 1 met?
boolean
C1516637 (UMLS CUI [1])
Eligibility Criteria
Item
If No, which of the 4 criteria was/were not met? Criteria 2 met?
boolean
C1516637 (UMLS CUI [1])
Eligibility Criteria
Item
If No, which of the 4 criteria was/were not met? Criteria 3 met?
boolean
C1516637 (UMLS CUI [1])
Eligibility Criteria
Item
If No, which of the 4 criteria was/were not met? Criteria 4 met?
boolean
C1516637 (UMLS CUI [1])
Item
lf any eligibility criteria were not met, was an exemption granted by OSI?
integer
C1516637 (UMLS CUI [1,1])
C2348482 (UMLS CUI [1,2])
Exemption
Code List
lf any eligibility criteria were not met, was an exemption granted by OSI?
CL Item
Yes (1)
CL Item
No (2)
CL Item
NA (3)
Item Group
Investigator Signature
Investigator Signature
Item
Investigator's Signature:
text
C2346576 (UMLS CUI [1])
Investigator Signature Date
Item
Date
date
C2346576 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial